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| INTRODUCTION
Patients with the bleeding disorder von Willebrand disease (VWD) type 2A have a severe defect in von Willebrand factor (VWF).
Laboratory diagnosis is based on the detection of an impaired VWF function reflected in VWF collagen binding and VWF ristocetin cofactor activities over VWF antigen ratios (VWF:CB/VWF:Ag and VWF:RCo/VWF:Ag) below 0.7 and a decrease (severe or mild) or lack of the high molecular weight (HMW) VWF multimers, depending on the location of the mutation. 1, 2 Patients implanted with left ventricular assist devices (LVAD) suffer from acquired von Willebrand syndrome (aVWS). [3] [4] [5] [6] [7] [8] [9] [10] However, the impaired VWF function is not always detected in the VWF:CB/VWF:Ag and VWF:RCo/VWF:Ag ratios but is reflected by a loss of HMW VWF multimers. 5, 6, 8, 11, 12 The aim of this study was to perform an analysis of VWF function in VWD type 2A and LVAD-induced aVWS patients to highlight to non-experts in the field that VWF function in LVAD patients is less impaired than in VWD type 2A patients and that VWF multimer analysis is the gold standard to detect aVWS in LVAD patients. on a microtiter plate, adding the different plasmas and detecting bound VWF using HRP-labelled polyclonal anti-VWF antibodies. 15, 16 A normal human plasma pool (NHP) was used to set up a calibration curve and undiluted plasma was set at 100% VWF:CB. Next, the VWF:CB/VWF:Ag and VWF:RCo/VWF:Ag ratios were calculated. VWF multimers were separated on a 1.2% sodium dodecyl sulphate (SDS) 1.5% isoelectric focusing (IEF) agarose gel and fixed on a Gelbond (Cambrex Bio Science Rockland Inc., Rockland, ME, USA). 17, 18 VWF was detected with an alkaline phosphatase (AP) labelled anti-human VWF antibody and an AP conjugate substrate kit (BioRad, Hercules, CA, USA).
| PATIENTS AND METHODS

| Patients
Densitometric analysis was performed using ImageJ software (version 1.47, NIH, Bethesda, MD, USA). The lowest (band 1-5, low molecular weight, LMW), the medium (band 6-10, medium molecular weight, MMW), and high molecular weight (HMW band >10) multimers were selected and the density of the HMW multimers relative to the total multimer density was calculated as a percentage.
| Statistical analysis
Significance between datasets was assessed with the one-way ANOVA test with corrections for multiple comparisons (Prism Version 6, GraphPad). P values were calculated comparing median values using P < 0.05 as a cut-off for significance. Data are represented as median with interquartile ranges.
Essentials
• VWF is defective in VWD type 2A and LVAD-induced aVWS patients.
• The difference in VWF function and multimers were studied in these two groups.
• VWF multimers were decreased in all VWD type 2A and LVAD patients in contrast to VWF function.
• Hence, VWF multimer analysis is the gold standard for diagnosis of aVWS in LVAD patients.
| RESULTS/DISCUSSION
In this study, we wanted to highlight the differences in VWF function between VWD type 2A patients and LVAD-induced aVWS decreased when compared to healthy individuals and are given in Figure 1D , in VWD type 2A patients, P < 0.001, Figure 1A In LVAD patients however, HMW VWF multimers are mildly decreased which is reflected in a moderate defect in VWF activity. Indeed, we and others 8, 12 show that VWF:CB/VWF:Ag and VWF:RCo/VWF:Ag ratios are not always below 0.7 in LVAD patients. As a consequence, VWF multimer analysis is the gold standard to detect aVWS in these patients. 5, 19 Comparable findings were obtained for aortic stenosis patients, in which aVWS has also been frequently detected. 20, 21 As multimer analysis is a time-consuming technique, an ELISA-based method was proposed as an alternative to detect VWF proteolysis. 7 We also determined if there was a correlation between the ratios of VWF parameters or the loss of HMW VWF multimers and the occurrence of bleeding, but no relationship was found. None of the patients experienced bleedings between four and six months after implantation of the device despite the loss of HMW VWF multimers or decreased VWF:CB/VWF:Ag and VWF:RCo/VWF:Ag ratios. These findings are in line with what is generally described in literature 4, 6, 22 suggesting that the loss of HMW VWF multimers alone does not account for the bleeding complications observed in the LVAD patients.
| CONCLUSION
In conclusion, we want to emphasize that VWF function in heart failure patients on LVAD support is much less impaired compared to VWD type 2A patients and that multimer analysis should always be performed to detect aVWS in LVAD patients.
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